UnitedHealth Group reported a medical care ratio in 2024 of 85.5% compared with 83.2% in 2023.
In 2024, UnitedHealth Group saw full year revenue grow 8% over 2023 to reach $400.3 billion. Adjusted earnings from operations, excluding costs related to last year’s cyberattack on Change Healthcare and the company’s sale of its South American operations, were $34.4 billion for full year 2024.
UnitedHealth Group reported a medical care ratio in 2024 of 85.5% compared with 83.2% in 2023. In a news release, company executives said this increase in the medical care ratio was due to CMS’s Medicare funding reductions, member mix and timing of Medicaid redeterminations. Other factors from the third quarter — increased hospital coding intensity and specialty medication prescribing — continued to impact the company in the fourth quarter.
2024 revenue for company’s health insurance division, UnitedHealthcare, increased 6% to $298.4 billion. The number of people served through the commercial plans grew by 2.4 million last year. In Medicare, the number of enrollees grew by 9.4 million, but in Medicaid enrollment “moderated,” according to the company because of eligibility redeterminations.
Within Optum Health, revenue grew 12% in 2024 over 2023, which the company said was led by Optum Rx and Optum Health.
Optum Rx, which provides pharmacy benefit services, saw revenue in 2024 increase by 15%. The number of adjusted scripts grew to 1.62 billion, compared with 1.54 billion in 2023
“The people of UnitedHealth Group remain focused on making high-quality, affordable health care more available to more people while making the health system easier to navigate for patients and providers, positioning us well for growth in 2025,” Andrew Witty, chief executive officer of UnitedHealth Group, said in the news release.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
ICER Identifies 5 Drugs with Unsupported Price Increases
December 12th 2024The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Read More